I agree with your Biogen sentiment Xena - question I have is what will Biogen do if they decide to pull the string on a deal with Anavex? Work out a licensing deal for 2-73 just for MS or for all indications or attempt to buy the whole company? I think they have the funds to do any of those things.
Does the downward trajectory of the AAIC results cause you concern? Missling said Sigma-1 drugs have a huge affect right after patients go on them, but we didn't see that in the trial. No dramatic spike up like we even see to some extent right off the bat with donepezil during first month and second
Market Data 
Markets 
AI
